SKYRIZI
Google image searchProduct monograph
Active ingredient
risankizumab, 360 MG/2.4 ML
DIN: 02532093
Dosage form(s): SOLUTION
Route(s) of administration: SUBCUTANEOUS
Description: PRE-FILLED CATRIDGE WITH ON-BODY INJECTOR
Schedule: Prescription / Schedule D
Company: ABBVIE CORPORATION
Date: 14-MAR-2023
ATC:
- L04 — IMMUNOSUPPRESSANTS (ATC, ATC/DDD, )
- L04A — IMMUNOSUPPRESSANTS (ATC, ATC/DDD)
- L04AC — Interleukin inhibitors (ATC, ATC/DDD)
- L04AC18 — RIZANKIZUMAB (ATC/DDD)
